JP2024504124A5 - - Google Patents
Info
- Publication number
- JP2024504124A5 JP2024504124A5 JP2023543120A JP2023543120A JP2024504124A5 JP 2024504124 A5 JP2024504124 A5 JP 2024504124A5 JP 2023543120 A JP2023543120 A JP 2023543120A JP 2023543120 A JP2023543120 A JP 2023543120A JP 2024504124 A5 JP2024504124 A5 JP 2024504124A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- cancer
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/072397 | 2021-01-18 | ||
| CN2021072397 | 2021-01-18 | ||
| CN2021142043 | 2021-12-28 | ||
| CNPCT/CN2021/142043 | 2021-12-28 | ||
| PCT/CN2022/072297 WO2022152290A1 (en) | 2021-01-18 | 2022-01-17 | Novel anti-gremlin1 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024504124A JP2024504124A (ja) | 2024-01-30 |
| JP2024504124A5 true JP2024504124A5 (enExample) | 2025-01-24 |
| JP7879131B2 JP7879131B2 (ja) | 2026-06-23 |
Family
ID=82446960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023543120A Active JP7879131B2 (ja) | 2021-01-18 | 2022-01-17 | 新規の抗グレムリン１抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240294622A1 (enExample) |
| EP (1) | EP4277927A4 (enExample) |
| JP (1) | JP7879131B2 (enExample) |
| KR (1) | KR20230132544A (enExample) |
| CN (1) | CN116848135A (enExample) |
| AU (1) | AU2022207030A1 (enExample) |
| CA (1) | CA3208455A1 (enExample) |
| MX (1) | MX2023008423A (enExample) |
| TW (1) | TW202241944A (enExample) |
| WO (1) | WO2022152290A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230156936A (ko) * | 2021-03-11 | 2023-11-15 | 상하이 지아오통 대학 | 그렘린1 길항제를 사용하여 질환을 치료하는 방법 |
| GB202205203D0 (en) * | 2022-04-08 | 2022-05-25 | UCB Biopharma SRL | Combination with inhibitor |
| GB202205200D0 (en) * | 2022-04-08 | 2022-05-25 | Ucb Biopharma Sprl | Combination with chemotherapy |
| KR20250169623A (ko) * | 2023-04-13 | 2025-12-03 | 쑤저우 트랜스센타 테라퓨틱스 컴퍼니 리미티드 | 암 치료를 위한 grem1 길항제를 수반하는 조합 요법 |
| TW202541848A (zh) * | 2024-01-08 | 2025-11-01 | 中國大陸商蘇州創勝醫藥集團有限公司 | 用於治療ｐａｈ之ｇｒｅｍ１拮抗劑及活化素受體拮抗劑的組合療法 |
| CN117801109B (zh) * | 2024-03-01 | 2024-05-03 | 再少年(北京)生物科技有限公司 | iPS诱导定向分化成内皮祖细胞的方法及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013137686A1 (ko) | 2012-03-15 | 2013-09-19 | 서울대학교 산학협력단 | 그렘린-1에 대한 항체 |
| BR112015021979A2 (pt) * | 2013-03-14 | 2017-08-29 | Regeneron Pharma | Anticorpos humanos para grem1 |
| CN109641954A (zh) | 2016-08-29 | 2019-04-16 | 里珍纳龙药品有限公司 | 抗-gremlin-1(grem1)抗体及其用于治疗肺动脉高血压的使用方法 |
| GB201621635D0 (en) | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
| AU2019289176B2 (en) | 2018-06-18 | 2026-02-19 | Adelaide university | Gremlin-1 antagonist for the prevention and treatment of cancer |
| KR20230156936A (ko) * | 2021-03-11 | 2023-11-15 | 상하이 지아오통 대학 | 그렘린1 길항제를 사용하여 질환을 치료하는 방법 |
-
2022
- 2022-01-17 AU AU2022207030A patent/AU2022207030A1/en active Pending
- 2022-01-17 MX MX2023008423A patent/MX2023008423A/es unknown
- 2022-01-17 WO PCT/CN2022/072297 patent/WO2022152290A1/en not_active Ceased
- 2022-01-17 US US18/261,834 patent/US20240294622A1/en active Pending
- 2022-01-17 EP EP22739165.3A patent/EP4277927A4/en active Pending
- 2022-01-17 KR KR1020237027807A patent/KR20230132544A/ko active Pending
- 2022-01-17 CN CN202280010207.XA patent/CN116848135A/zh active Pending
- 2022-01-17 JP JP2023543120A patent/JP7879131B2/ja active Active
- 2022-01-17 CA CA3208455A patent/CA3208455A1/en active Pending
- 2022-01-18 TW TW111102041A patent/TW202241944A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7857980B2 (ja) | Ｃｄ１９指向性キメラ抗原受容体および免疫療法におけるその使用 | |
| EP3237006B1 (en) | Bispecific tetravalent antibodies and methods of making and using thereof | |
| JP2022515318A5 (enExample) | ||
| JP2022526764A5 (enExample) | ||
| JP6039428B2 (ja) | 抗ｈｅｒ２抗体および組成物 | |
| JP2023539501A5 (enExample) | ||
| RU2016125551A (ru) | Биспецифические антигенсвязывающие конструкции против her2 | |
| JP2024531409A5 (enExample) | ||
| JP2024513692A5 (enExample) | ||
| JP2024534468A5 (enExample) | ||
| JPWO2021177438A5 (enExample) | ||
| JP2023537002A5 (enExample) | ||
| JP2024519335A (ja) | がん免疫療法のための投薬レジメン | |
| JP2022512891A5 (enExample) | ||
| JP2021520201A5 (enExample) | ||
| JP2025508066A (ja) | 目的としたｔ細胞活性化のためのｃｄ２８二重特異性抗体 | |
| JP2022526841A5 (enExample) | ||
| JP2024515560A5 (enExample) | ||
| JP2023534959A5 (enExample) | ||
| Jachimowicz et al. | Multi-specific antibodies for cancer immunotherapy | |
| TW202430553A (zh) | Psma抗體及其用途 | |
| JP2023525991A5 (enExample) | ||
| CN119997974A (zh) | 一种异源二聚体融合蛋白及其应用 | |
| JP2025516590A5 (enExample) | ||
| CN114685675B (zh) | 双特异性抗体及其在治疗癌症中的用途 |